Another is the treatment of congenital neutropenia patients with compromising mutations to the Ig-like domain and its binding site in G-CSFR, where such patients are unresponsive to rhG-CSF, which requires two different binding sites to dimerise the receptor, unlike the designs. This evidence concerns the gene CSF3R and severe congenital neutropenia.